StreetInsider.com News Articles

Form DEFA14A OPKO HEALTH, INC.

Fri, 15 May 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260515/26507044.html

Form DEFA14A OPKO HEALTH, INC.

Fri, 15 May 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260515/26507044.html

OPKO's ModeX to present CAR-T cell generation data at gene therapy meeting

Tue, 12 May 2026 08:00:52 -0400

ModeX Therapeutics, a subsidiary of OPKO Health (NASDAQ: OPK), will present preclinical data on its MDX3001 candidate at the American Society of Gene & Cell Therapy 2026 Annual Meeting in Boston from May 11-15.

The data demonstrates in vivo generation of CAR-T cells and B-cell depletion using the company's CD3xCD28 antibody-conjugated lipid nanoparticle/mRNA platform in animal models. Studies showed B-cell depletion in blood and lymphoid tissues including spleen, bone marrow, and lymph nodes in both humanized mouse and non-human primate models.

The platform combines CD3 with CD28 costimulatory engagement to enable T-cell transfection, activation, and functional CAR-T cell generation directly in vivo.

OPKO's ModeX to present CAR-T cell generation data at gene therapy meeting

Tue, 12 May 2026 08:00:52 -0400

The platform combines CD3 with CD28 costimulatory engagement to enable T-cell transfection, activation, and functional CAR-T cell generation directly in vivo.

OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies

Tue, 12 May 2026 08:00:00 -0400

Multispecific antibody conjugated LNP/mRNA platform enables in vivo T-cell engineering and systemic B-cell depletion in animal models

Data will be presented at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

WESTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), will announce preclinical data demonstrating the in vivo generation of CAR-T cells and deep systemic B-cell depletion achieved with its MDX3001 candidate in animal models. The data, generated using ModeX’s CD3xCD28 antibody-conjugated lipid nanoparticle (LNP)/mRNA platform, will be presented at the ASGCT 2026 Annual

OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies

Tue, 12 May 2026 08:00:00 -0400

Multispecific antibody conjugated LNP/mRNA platform enables in vivo T-cell engineering and systemic B-cell depletion in animal models

Data will be presented at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies

Tue, 12 May 2026 08:00:00 -0400

Multispecific antibody conjugated LNP/mRNA platform enables in vivo T-cell engineering and systemic B-cell depletion in animal models

Data will be presented at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies

Tue, 12 May 2026 08:00:00 -0400

Multispecific antibody conjugated LNP/mRNA platform enables in vivo T-cell engineering and systemic B-cell depletion in animal models

Data will be presented at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

Form DEFA14A OPKO HEALTH, INC.

Thu, 30 Apr 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260430/26407533.html

Form DEFA14A OPKO HEALTH, INC.

Thu, 30 Apr 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260430/26407533.html

Form ARS OPKO HEALTH, INC. For: Dec 31

Thu, 30 Apr 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260430/26407611.html

Form ARS OPKO HEALTH, INC. For: Dec 31

Thu, 30 Apr 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260430/26407611.html

Form DEF 14A OPKO HEALTH, INC. For: Apr 30

Thu, 30 Apr 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260430/26407388.html

Form DEF 14A OPKO HEALTH, INC. For: Apr 30

Thu, 30 Apr 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260430/26407388.html

OPKO Health receives 15% stake in Nicoya for China drug rights

Thu, 30 Apr 2026 08:31:15 -0400

OPKO Health Inc. (NASDAQ: OPK) announced its subsidiary EirGen Pharma Limited amended an agreement with Nicoya Therapeutics (Macau) Limited, granting OPKO a 15% equity stake in Nicoya in exchange for revised royalty and transfer price terms for RAYALDEE commercialization in Greater China.

The amended agreement expands the original June 2021 deal for developing and commercializing RAYALDEE, a treatment for secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease. RAYALDEE has received approval in Macau, with regulatory approvals expected in China and related territories in 2027.

Under the revised terms, OPKO received Series A-2 Preferred Shares in Nicoya, set to

OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China